126 related articles for article (PubMed ID: 11309311)
21. ApcMin: a mouse model for intestinal and mammary tumorigenesis.
Moser AR; Luongo C; Gould KA; McNeley MK; Shoemaker AR; Dove WF
Eur J Cancer; 1995; 31A(7-8):1061-4. PubMed ID: 7576992
[TBL] [Abstract][Full Text] [Related]
22. The threshold level of adenomatous polyposis coli protein for mouse intestinal tumorigenesis.
Li Q; Ishikawa TO; Oshima M; Taketo MM
Cancer Res; 2005 Oct; 65(19):8622-7. PubMed ID: 16204028
[TBL] [Abstract][Full Text] [Related]
23. Mutations in Apc and p53 synergize to promote mammary neoplasia.
Méniel V; Hay T; Douglas-Jones A; Sansom OJ; Clarke AR
Cancer Res; 2005 Jan; 65(2):410-6. PubMed ID: 15695381
[TBL] [Abstract][Full Text] [Related]
24. Development of gastric tumors in Apc(Min/+) mice by the activation of the beta-catenin/Tcf signaling pathway.
Tomita H; Yamada Y; Oyama T; Hata K; Hirose Y; Hara A; Kunisada T; Sugiyama Y; Adachi Y; Linhart H; Mori H
Cancer Res; 2007 May; 67(9):4079-87. PubMed ID: 17483318
[TBL] [Abstract][Full Text] [Related]
25. Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis.
Zeilstra J; Joosten SP; Dokter M; Verwiel E; Spaargaren M; Pals ST
Cancer Res; 2008 May; 68(10):3655-61. PubMed ID: 18483247
[TBL] [Abstract][Full Text] [Related]
26. Impact of genetic background on spontaneous or 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced intestinal tumorigenesis in Min/+ mice.
Steffensen IL; Alexander J
Cancer Lett; 2006 Aug; 240(2):289-96. PubMed ID: 16343741
[TBL] [Abstract][Full Text] [Related]
27. Role of nucleotide excision repair deficiency in intestinal tumorigenesis in multiple intestinal neoplasia (Min) mice.
Steffensen IL; Schut HA; Nesland JM; Tanaka K; Alexander J
Mutat Res; 2006 Dec; 611(1-2):71-82. PubMed ID: 16962818
[TBL] [Abstract][Full Text] [Related]
28. C57BR/cdJ hepatocarcinogen susceptibility genes act cell-autonomously in C57BR/cdJ<-->C57BL/6J chimeras.
Chiaverotti TA; Drinkwater NR
Cancer Res; 2003 Aug; 63(16):4914-9. PubMed ID: 12941815
[TBL] [Abstract][Full Text] [Related]
29. Phospholipase Cepsilon promotes intestinal tumorigenesis of Apc(Min/+) mice through augmentation of inflammation and angiogenesis.
Li M; Edamatsu H; Kitazawa R; Kitazawa S; Kataoka T
Carcinogenesis; 2009 Aug; 30(8):1424-32. PubMed ID: 19458037
[TBL] [Abstract][Full Text] [Related]
30. The APC tumor suppressor is required for epithelial integrity in the mouse mammary gland.
Prosperi JR; Becher KR; Willson TA; Collins MH; Witte DP; Goss KH
J Cell Physiol; 2009 Aug; 220(2):319-31. PubMed ID: 19326388
[TBL] [Abstract][Full Text] [Related]
31. Genetic determinants modulate susceptibility to pregnancy-associated tumourigenesis in a recombinant line of Min mice.
Suraweera N; Haines J; McCart A; Rogers P; Latchford A; Coster M; Polanco-Echeverry G; Guenther T; Wang J; Sieber O; Tomlinson I; Silver A
Hum Mol Genet; 2006 Dec; 15(23):3429-35. PubMed ID: 17062636
[TBL] [Abstract][Full Text] [Related]
32. A quantitative trait locus on chromosome 18 is a critical determinant of excitotoxic cell death susceptibility.
Lorenzana A; Chancer Z; Schauwecker PE
Eur J Neurosci; 2007 Apr; 25(7):1998-2008. PubMed ID: 17439488
[TBL] [Abstract][Full Text] [Related]
33. Apc mice: models, modifiers and mutants.
McCart AE; Vickaryous NK; Silver A
Pathol Res Pract; 2008; 204(7):479-90. PubMed ID: 18538487
[TBL] [Abstract][Full Text] [Related]
34. The Mcs7 quantitative trait locus is associated with an increased susceptibility to mammary cancer in congenic rats and an allele-specific imbalance.
Cotroneo MS; Merry GM; Haag JD; Lan H; Shepel LA; Gould MN
Oncogene; 2006 Aug; 25(36):5011-7. PubMed ID: 16568087
[TBL] [Abstract][Full Text] [Related]
35. The anti-ischemia agent ranolazine promotes the development of intestinal tumors in APC(Min/+) mice.
Suckow MA; Gutierrez LS; Risatti CA; Wolter WR; Taylor RE; Pollard M; Navari RM; Castellino FJ; Paoni NF
Cancer Lett; 2004 Jun; 209(2):165-9. PubMed ID: 15159018
[TBL] [Abstract][Full Text] [Related]
36. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
[TBL] [Abstract][Full Text] [Related]
37. Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic mice.
van Rossum AG; van Bragt MP; Schuuring-Scholtes E; van der Ploeg JC; van Krieken JH; Kluin PM; Schuuring E
BMC Cancer; 2006 Mar; 6():58. PubMed ID: 16536875
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of intestinal polyposis with reduced angiogenesis in ApcMin/+ mice due to decreases in c-Myc expression.
Yekkala K; Baudino TA
Mol Cancer Res; 2007 Dec; 5(12):1296-303. PubMed ID: 18171987
[TBL] [Abstract][Full Text] [Related]
39. Persistent mammary hyperplasia in FVB/N mice.
Nieto AI; Shyamala G; Galvez JJ; Thordarson G; Wakefield LM; Cardiff RD
Comp Med; 2003 Aug; 53(4):433-8. PubMed ID: 14524420
[TBL] [Abstract][Full Text] [Related]
40. Intestinal immune responses in wild-type and Apcmin/+ mouse, a model for colon cancer.
Kettunen HL; Kettunen AS; Rautonen NE
Cancer Res; 2003 Aug; 63(16):5136-42. PubMed ID: 12941845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
